Dr. Samra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8300 Constitution Ave NE
Albuquerque, NM 87110Phone+1 505-559-6100Fax+1 505-559-6649
Summary
- I am a board certified hematologist and medical oncologist. I provide a general and comprehensive care for cancer and blood disorders to the local community. My clinical expertise is hematologic malignancies especially leukemia. I focus in my practice on patient education and empowerment as part of a shared decision making. I aspire to deliver the highest standards of clinical care, to diminish the gap of healthcare disparities, and to help guide my patients through their difficult journey.
Education & Training
University of Texas M.D. Anderson Cancer CenterFellowship, Leukemia, 2019 - 2020
SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2016 - 2019
Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 2013 - 2016
St Joseph's University Medical SchoolClass of 2012
Certifications & Licensure
NM State Medical License 2019 - 2026
TX State Medical License 2024 - 2025
OK State Medical License 2015 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- ASH Abstract Achievement Award American Society of Hematology, 2019
- Chief Fellow-Hematology/Oncology SUNY Downstate, 2018-2019
Publications & Presentations
PubMed
- 9 citationsScreening Strategies for COVID-19 in Patients With Hematologic MalignanciesTarek Assi, Bachar Samra, Laurent Dercle, Elie El Rassy, Joseph Kattan
Frontiers in Oncology. 2020-07-03 - 17 citationsCharacteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.Bachar Samra, Guillaume Richard-Carpentier, Tapan M. Kadia, Farhad Ravandi, Naval Daver
Blood Cancer Journal. 2020-05-04 - 24 citationsCheckpoint inhibitors in head and neck cancer: current knowledge and perspectives.Bachar Samra, Eric Tam, Babak Baseri, Iuliana Shapira
Journal of Investigative Medicine. 2018-10-01
Books/Book Chapters
Abstracts/Posters
- Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)Bachar Samra, Hagop M. Kantarjian, Koji Sasaki, Marina Y Konopleva, Rita Khouri, Susan M. O'Brien, Alessandra Ferrajoli, Cesar Nunez, Tapan M. Kadia, Elias Jabbour, American Society of Hematology (ASH) 2019 Annual Meeting, Orlando, FL, 12/2/2019
- Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)Bachar Samra, Hagop M. Kantarjian, Koji Sasaki, Nicholas J. Short, Rita Khouri, Joseph D. Khoury, Richard E. Champlin, Partow Kebriaei, Jorge E. Cortes, Jeffrey L. Jor..., American Society of Hematology (ASH) 2019 Annual Meeting, Orlando, FL, 12/2/2019
- Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...Koji Sasaki, Hagop M. Kantarjian, Bachar Samra, Nicholas J. Short, Joseph D. Khoury, Rashmi Kanagal-Shamanna, Marina Y Konopleva, Nitin Jain, Courtney D. DiNardo, Rita..., American Society of Hematology (ASH) 2019 Annual Meeting, Orlando, FL, 12/1/2019
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Arabic, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
